Deal round-up 21/03/03

Granville Baird backs Amann Druckguss growth; Nomura backs $46m healthcare round; GIMV, Big Bang lead ORMvision round; German pharma company lands E30m series C financing; Banexi joins La Toulousaine MBO

Granville Baird backs Amann Druckguss growth

 

Granville Baird Capital Partners, the European private equity unit of Robert W. Baird, has provided growth capital for Amann Druckguss, a German automobile supplier and die-casting specialist based in Massenbach­hausen, Germany.

 

'In the next three years we are planning to invest almost E10m and hire an additional 50 employees,” said Joachim Amann, managing director of Amann Druckguss. The company currently employs 250 people and counts Daimler-Chrysler, Porsche and Bosch among its clients.

 

Nomura backs $46m healthcare round

 

Healthcare Private Equity Group, the London-based private equity unit of Nomura International, has backed a $46m financing round for Targacept, a US-based healthcare company focused on central nervous system diseases. Targacept will use the funds to advance its current programs into late stage clinical development and to progress its pre-clinical programs.

 

In addition to Nomura, other new investors participating in this financing round were New Enterprise Associates (NEA), CDIB BioScience Ventures and Easton Hunt Capital Partners. Also participating were investors from Targacept’s first round financing: EuclidSR Partners, Burrill & Company, Advent Venture Partners, Auriga Ventures, CDC-IXIS Innovation, Genavent Fund, Société Générale Asset Management Finance and Academy Venture Fund.

 

GIMV, Big Bang lead ORMvision round

 

Belgian venture capital firms GIMV and Big Bang Ventures have provided E1m in financing for ORMvision, a Belgium-based telecommunications software developer. The capital will enable the firm to further develop its ORMcenter software suite and and expand its operations into new markets.

 

ORMvision was founded in 2000 to develop a platform to enable telecom operators to communicate effectively. The company closed a E500,000 seed round of funding in May 2001 with Big Bang Ventures and a second round of E2m with GIMV and Big Bang Ventures in October 2001.

 

German pharma company lands E30m series C financing

 

A group of international venture capital firms led by INVESCO Private Capital has provided Cellzone, a proteomics research business, with E30m in series C financing. The funds raised in this round will be used to fund research and development and proof-of-concept studies.

 

The company, based in Heidelberg, Germany, has also secured investment from Biofrontier Partners, SG Asset Management, Yamanouchi Venture Capital, as well as existing investors Advent International, Atlas Venture, Index Ventures, Heidelberg Innovation, Schroder Ventures Life Sciences and Sofinnova Partners. SG Cowen was the placement agent.

 

Banexi joins La Toulousaine MBO

 

Middle Market Fund II, a fund managed by Banexi Capital Partenaires, has backed management led by Yves Cordonnier in the acquisition of La Toulousaine, a French manufacturer of safety shutters and gates for stores and shops.

 

Banexi has acquired the business from 3i and Spef/Banques Populaires. The financial details have not been disclosed, although the company reported turnover last year of E31m, up ten per cent on the previous year.